HeartBeam (NASDAQ: BEAT), a medical technology company advancing cardiac care, has submitted a 510(k) application to the U.S. Food and Drug Administration (“FDA”) for its 12-lead electrocardiogram (“ECG”) synthesis software. The software is designed to assess cardiac rhythms and arrhythmias, … Continue reading →

HeartBeam (NASDAQ: BEAT) has received FDA 510(k) clearance for its groundbreaking HeartBeam system, a credit card-sized, cable-free ECG device designed for comprehensive arrhythmia assessment. The system enables patients to record high-fidelity heart signals from three directions during symptoms, with data … Continue reading →

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, today announced the results from two studies evaluating its groundbreaking vector-based technology. According to the announcement, the data add … Continue reading →

HeartBeam (NASDAQ: BEAT), a medical technology company focused on enhancing cardiac care through advanced insights, will hold a conference call on November 7, 2024, at 4:30 p.m. ET to discuss third-quarter results and share updates on regulatory developments and ongoing … Continue reading →

HeartBeam (NASDAQ: BEAT), a medical technology company focused on advancing cardiac care, was recognized with the 2024 Digital Health Hub Rising Star award in the ‘Home Health Diagnostic’ category at the HLTH global healthcare conference. The award highlights HeartBeam’s innovative … Continue reading →

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has named a seasoned medtech leader as its new chief financial officer. According to the announcement, Timothy Cruickshank has accepted the role … Continue reading →

HeartBeam(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has scheduled a conference call and webcast to discuss its second-quarter 2024 results. According to the announcement, the call is slated to begin … Continue reading →

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced the results of a new study demonstrating that HeartBeam AI combined with vectorcardiography (“VCG”) outperformed an expert panel of heart … Continue reading →

HeartBeam(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, is presenting new data at the European Heart Rhythm Association (“EHRA”) Conference. According to the announcement, this is the first scientific presentation on … Continue reading →

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced its financial numbers and operational highlights for the fourth quarter and full year ended Dec. 31, 2023. According to the … Continue reading →